序号 | 专利名 | 申请号 | 申请日 | 公开(公告)号 | 公开(公告)日 | 发明人 |
---|---|---|---|---|---|---|
181 | Liquid crystal compounds having ether tail moiety | EP87110034.3 | 1987-07-11 | EP0258578A3 | 1989-05-10 | Cumming, William J.; Gaudiana, R. A.; McGowan, Cynthia; Minns, Richard A.; Naiman, Alaric |
Disclosed are smectic liquid crystal compounds exhibiting ferroelectric behaviour and having the formula
|
||||||
182 | OPTICALLY ACTIVE, ANTI HEAD-TO-HEAD COUMARIN DIMER-POLYAMIDES | EP85900728.8 | 1985-01-07 | EP0207993A1 | 1987-01-14 | SAIGOU, Kazuhiko; YONEZAWA, Noriyuki; KANOE, Toshio; SEKIMOTO, Kazuhiro |
Optically active, anti head-to-head coumarin dimers represented by general formula (I) or (II): a process for their preparation, optically active polyamides represented by general formula (III) or (IV), (wherein A represents a primary or secondary amine residue, and n represents an integer of 2 or more) and a process for their preparation from (I) or (II). |
||||||
183 | Reagents, test kits and methods for the detection of cannabinoids | EP84304306.8 | 1984-06-26 | EP0132313A2 | 1985-01-30 | Spiro, Baruch |
The invention provides a stable solid reagent for use in a prepackaged test kit for the detection of cannabinoids comprising a diazonium salt which undergoes characteristic color change when combined with a cannabinoid under basic conditions, the salt comprising an anion capable of causing the entire salt including the diazonium cation thereof to dissolve in an organic solvent when combined therewith to form a stable liquid reagent for the detection of cannabinoids. The invention also provides a stable liquid reagent comprising the aforementioned diazonium salt and an organic solvent as well as providing prepackaged reagent test kits containing the aforementioned reagents and methods for detecting cannabinoids using the reagents of the invention. |
||||||
184 | Azophenols as ERG oncogene inhibitors | AU2016319111 | 2016-09-09 | AU2016319111B2 | 2021-05-06 | DOBI ALBERT L; DALGARD CLIFTON; SRIVASTAVA SHIV |
Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II), wherein X, X1, X2, X3, X4, X5, R1 through R4 and R9 are as described. An aspect of the present invention relates to a method for treating a disease associated with overexpression of wild type ERG protein, an altered ERG protein, ERG gene transcription or ERG mRNA translation in a subject suffering therefrom, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or Formula (II) | ||||||
185 | ACYLHYDRAZONES FOR THE TREATMENT OF NEUROLOGICAL DISEASES | CA3114555 | 2019-09-27 | CA3114555A1 | 2020-04-02 | PEREZ FERNANDEZ RUTH; CANAL MARTIN ANDREA; SANCHEZ BARRENA MARIA JOSE; MANSILLA APARICIO ALICIA |
The invention relates to a group of compounds with a structural nucleus of acylhydrazone, which are capable of modulating the interaction between the proteins NCS-1 and Ric8a involved in the process of regulating the number of synapses and the probability of release of neurotransmitters. These compounds can therefore be used for the treatment of neurological diseases in which the number of synapses is affected, such as Alzheimer's disease, Huntington's disease or Parkinson's disease. | ||||||
186 | AZOPHENOLS AS ERG ONCOGENE INHIBITORS | CA2981188 | 2016-09-09 | CA2981188A1 | 2017-03-16 | DOBI ALBERT L; DALGARD CLIFTON; SRIVASTAVA SHIV |
Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II), wherein X, X1, X2, X3, X4, X5, R1 through R4 and R9 are as described. An aspect of the present invention relates to a method for treating a disease associated with overexpression of wild type ERG protein, an altered ERG protein, ERG gene transcription or ERG mRNA translation in a subject suffering therefrom, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or Formula (II) | ||||||
187 | АЗО-БІС-[ІЗОБУТИРООКСАДІАЗОЛІНІЛЦИКЛОГЕКСИЛКАРБАМАТ-(1-ГЕКСАМЕТИЛЕН-3,5-ДИГЕКСАМЕТИЛЕНІЗОЦІАНАТ)ЦІАНУРАТ] ЯК ІНІЦІАТОР РАДИКАЛЬНОЇ ПОЛІМЕРИЗАЦІЇ ВІНІЛОВИХ МОНОМЕРІВ | UAU201403468 | 2014-04-04 | UA92918U | 2014-09-10 | HRYSCHENKO VOLODYMYR KOSTIANTYNOVYCH; BUSKO NATALIA ANATOLIIVNA; SILCHENKO YURII OLEKSIIOVYCH; HUDZENKO NATALIA VASYLIVNA; KOCHETOVA YAROSLAVA VASYLIVNA; BARANTSOVA ANTONINA VIKTORIVNA |
Азо-біс-[ізобутирооксадіазолінілциклогексилкарбамат-(1-гексаметилен-3,5-дигексаметиленізоціанат)ціанурат] якініціаторрадикальноїполімеризаціївініловихмономерів. | ||||||
188 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | CA2431083 | 2001-12-18 | CA2431083C | 2011-08-09 | MUTO SUSUMU; NAGANO TATSUO; SOTOME TOMOMI; ITAI AKIKO |
A medicament having inhibitory activity against NF- .kappa. B activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: (see formula I) wherein X represents a connecting group, A represents hydrogen atom or acetyl group, E represents an aryl group or a heteroaryl group, and ring X represents an arene or a heteroarene. | ||||||
189 | ПЕРФТОРАРОМАТИЧЕСКИЕ ИЗОМЕРНЫЕ АЗОБИСФЕНОЛЫ КАК МОНОМЕРЫ ДЛЯ ПОЛИУРЕТАНОВ | UAU201100359 | 2011-01-12 | UA61268U | 2011-07-11 | SHEVCHENKO VALERII VASYLIOVYCH; TKACHENKO IHOR MYKHAILOVYCH; SYDORENKO OLEKSANDR VASYLIOVYCH; KONONEVYCH YURII MYKOLAIOVYCH; SHEKERA OLEH VASYLOVYCH |
Перфторароматическиеизомерныеазобисфенолыобщейформулы EMBED ISISServer , где 1 - n-АБФ, 2 - м-АБФи 3 - о-АБФкакмономерыдляполиуретанов. | ||||||
190 | ПЕРФТОРАРОМАТИЧЕСКИЕ ИЗОМЕРНЫЕ БИСФЕНОЛЫ С АЗОГРУППАМИ КАК МОНОМЕРЫ ДЛЯ ПОЛИЭТЕРУРЕТАНОВ | UAU201004461 | 2010-04-16 | UA53567U | 2010-10-11 | SHEVCHENKO VALERII VASYLIOVYCH; TKACHENKO IHOR MYKHAILOVYCH; KONONEVYCH YURII MYKOLAIOVYCH; SYDORENKO OLEKSANDR VASYLIOVYCH; SHEKERA OLEH VASYLOVYCH |
Перфторароматическиеизомерныебисфенолыс азогруппамикакмономерыдляполиэтеруретанов. | ||||||
191 | АМИД 2,2'-АЗО-БИС-ИЗОМАСЛЯНОЙ КИСЛОТЫ КАК ИНИЦИАТОР РАДИКАЛЬНОЙ ПОЛИМЕРИЗАЦИИ ДИЕНОВЫХ И ВИНИЛОВЫХ МОНОМЕРОВ | UAU200906369 | 2009-06-19 | UA47180U | 2010-01-25 | HRYSCHENKO VOLODYMYR KOSTIANTYNOVYCH; HUDZENKO NATALIA VASYLIVNA; BARANTSOVA ANTONINA VIKTORIVNA; BUSKO NATALIA ANATOLIIVNA |
Амид 2,2'-азо-бис-изомаслянойкислотыкакинициаторрадикальнойполимеризациидиеновыхи виниловыхмономеров. | ||||||
192 | АНТАГОНИСТЫ МУСКАРИНОВЫХ АЦЕТИЛХОЛИНОВЫХ РЕЦЕПТОРОВ | RU2006129289 | 2005-01-13 | RU2006129289A | 2008-02-20 | |
193 | Nowe związki, pochodne kwasu fumarowego oraz sposób wytwarzania nowych związków, pochodnych kwasu fumarowego | PL34587001 | 2001-02-13 | PL192547B1 | 2006-11-30 | BLUS KAZIMIERZ; WOJCIECHOWSKA ALEKSANDRA; WOJCIECHOWSKI KRZYSZTOF |
194 | Sposób wytwarzania nowych związków, pochodnych kwasu fumarowego | PL34590901 | 2001-02-14 | PL192540B1 | 2006-11-30 | BLUS KAZIMIERZ; WOJCIECHOWSKA ALEKSANDRA; WOJCIECHOWSKI KRZYSZTOF |
195 | NOVI N-MONOSUPSTITUISANI CIJANOACETAMIDI I POSTUPAK ZA NJIHOVO DOBIJANJE | YUP76803 | 2003-09-30 | YU76803A | 2006-05-25 | MARINKOVIC ALEKSANDAR; MIJIN DUSAN; NEDELJKOVIC JELENA; PETROVIC SLOBODAN |
Postupak za dobijanje novih supstituisanih N-supstituisanih-2-cijanoacetamida opšte formule (I) u kojoj R predstavlja s-butil, alil, cikloheksil, 4-hidroksifenil, 4-sulfonilfenil, 4-karboksifenil i 4-acetilfenil.[Method of preparation of new substituted N-substituted-2-cyanoacetamides having general formula as in (1) Wherein R represents s-butyl, allyl, cyclohexyl, 4-hydroxyphenyl, 4-sulphonylphenyl, 4-carboxyphenyl and 4-acetyphenyl. | ||||||
196 | Immunoregulatory Compounds and Derivatives and methods of treating diseases therewith | AU2005244526 | 2005-12-14 | AU2005244526A1 | 2006-01-12 | RIGGS-SAUTHIER JENNIFER; ELWURIBE NNOCHIRI N |
197 | Peptide deformylase inhibitors | AU2002335490 | 2002-03-01 | AU2002335490B2 | 2005-10-20 | XIANG JIA-NING; LEE JINHWA; MERCER DANIEL J; CHRISTENSEN SIEGFRIED B |
198 | PEPTIDE DEFORMYLASE INHIBITORS | PL36456302 | 2002-03-01 | PL364563A1 | 2004-12-13 | XIANG JIA-NING; CHRISTENSEN SIEGFRIED B; LEE JINHWA; MERCER DANIEL J |
199 | PROCESS FOR CONTROLLING PARTICLE SIZE OF NAPTHOQUINONE DIAZIDE | MYPI19985777 | 1998-12-21 | MY114500A | 2002-10-31 | JOSEPH E OBERLANDER |
A PROCESS FOR PRODUCING A NAPHTHOQUINONE DIAZIDE ESTER OF A PHENOLIC COMPOUND THAT IS USEFUL IN A PHOTORESIST COMPOSITION, WHICH PROCESS COMPRISES PROVIDING A NAPHTHOQUINONE DIAZIDE ESTER SOLUTION IN AN ORGANIC POLAR SOLVENT; ADDING THE RESULTING NAPHTHOQUINONE DIAZIDE ESTER SOLUTION TO A PRECIPITATION BATH THAT IS MAINTAINED AT A TEMPERATURE OF FROM ABOUT 0OC TO ABOUT -30OC; AND FILTERING THE RESULTING NAPHTHOQUINONE DIAZIDE ESTER. | ||||||
200 | Chemical compounds and pharmaceutical compositions for release of drugs | DE68929117 | 1989-03-31 | DE68929117T2 | 2000-08-24 | MILLS RANDELL L |